HKSE - Delayed Quote HKD

The United Laboratories International Holdings Limited (3933.HK)

9.480 -0.290 (-2.97%)
At close: April 26 at 4:08 PM GMT+8

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Mr. Hoi Shan Tsoi Executive Chairman 4.4M -- 1978
Mr. Wing Hon Leung CPA, FCPA Vice Chairman, CFO & Company Secretary 4.38M -- 1962
Ms. Su Yan Zhu VP & Executive Director 2.68M -- 1965
Ms. Xian Hong Zou VP & Executive Director 2.68M -- 1965
Ms. Siu Chit Choy Global Director of Intermediate & Bulk Medicine and Executive Director 2.93M -- 1973
Mr. Yu Ping Fang VP & Executive Director 2.72M -- 1963
Ms. Karen Yang Manager of Investor Relations -- -- --

The United Laboratories International Holdings Limited

6 Fuk Wang Street
Yuen Long Industrial Estate
Yuen Long
Hong Kong
852 2687 1033 https://www.tul.com.cn
Sector: 
Healthcare
Full Time Employees: 
15,000

Description

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin products, nervous system drugs, vitamins, veterinary drugs, and vacant gelatin capsules, as well as active pharmaceutical ingredients and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, rest of Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.

Corporate Governance

The United Laboratories International Holdings Limited’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Mar 26, 2024
The United Laboratories International Holdings Limited Earnings Call

Jun 17, 2024

Ex-Dividend Date

Related Tickers

4507.T Shionogi & Co., Ltd.
7,306.00
+2.21%
 
1498.HK PuraPharm Corporation Limited
0.750
0.00%
 
0867.HK China Medical System Holdings Limited
7.200
+1.84%
 
0013.HK HUTCHMED (China) Limited
30.350
0.00%
 
3320.HK China Resources Pharmaceutical Group Limited
5.040
+1.61%
 
2877.HK China Shineway Pharmaceutical Group Limited
9.600
+2.67%
 
1681.HK Consun Pharmaceutical Group Limited
5.670
-0.87%
 
3692.HK Hansoh Pharmaceutical Group Company Limited
17.220
+2.50%
 
OGI.TO Organigram Holdings Inc.
2.5700
+0.39%
 
VTRS Viatris Inc.
11.57
+0.87%